Mihanfar Aynaz, Rahmati-Yamchi Mohammad, Mota Ali, Abediazar Sima, Pilehvar-Soltanahmadi Younes, Zarghami Nosratollah
Department of Clinical Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Curr Diabetes Rev. 2018;14(2):162-167. doi: 10.2174/1573399813666170530103216.
Diabetic Nephropathy (DN), a serious and prevalent complication of diabetes, has been rapidly raising worldwide. Vaspin, as an adipokine with anti-diabetic effects, is predominantly released from visceral adipose tissue. Moreover, vaspin has the stimulatory effect on nitric oxide (NO) bioavailability through the activation of NO synthase.
The aim of the present study was to investigate the serum levels of vaspin and their correlation with NO metabolite in diabetic patients with normal renal function and renal insufficiency.
Volunteers patients with non-nephropathy Type 2 Diabetic Mellitus (T2DM) as control (n=40, age= 56.95±6.11 years) and patients with diabetic nephropathy (DN) (n=40, age=57.85±5.63 years) as case group were enrolled in this study, and serum samples were collected for the measurement of vaspin levels by ELISA technique. Also, serum levels of NO metabolites were calorimetrically assessed.
We found that vaspin levels significantly decreased in diabetic patients with nephropathic condition as compared with diabetic patients with normal renal function (p <0.04). In addition, serum levels of NO metabolites were significantly higher in diabetic patients with nephropathy in comparison with non-nephropathic diabetics (p<0.001). When patients with DN were studied, vaspin levels positively correlated with NO metabolites and Homeostasis model assessment of insulin resistance (HOMA-IR) levels.
This study showed that low serum vaspin levels may be a risk factor for nephropathy in type II diabetic patients and increased levels of NO may be a defensive mechanism in the DN.
糖尿病肾病（DN）是糖尿病一种严重且普遍的并发症，在全球范围内迅速增加。内脏脂肪素作为一种具有抗糖尿病作用的脂肪因子，主要从内脏脂肪组织释放。此外，内脏脂肪素通过激活一氧化氮合酶对一氧化氮（NO）的生物利用度具有刺激作用。
本研究旨在探讨肾功能正常和肾功能不全的糖尿病患者血清内脏脂肪素水平及其与NO代谢产物的相关性。
本研究纳入志愿者，将非肾病2型糖尿病（T2DM）患者作为对照组（n = 40，年龄 = 56.95±6.11岁），糖尿病肾病（DN）患者作为病例组（n = 40，年龄 = 57.85±5.63岁），收集血清样本，采用ELISA技术测定内脏脂肪素水平。此外，采用比色法评估血清NO代谢产物水平。
我们发现，与肾功能正常的糖尿病患者相比，肾病状态的糖尿病患者内脏脂肪素水平显著降低（p <0.04）。此外，与非肾病糖尿病患者相比，肾病糖尿病患者血清NO代谢产物水平显著更高（p<0.001）。在研究DN患者时，内脏脂肪素水平与NO代谢产物和胰岛素抵抗稳态模型评估（HOMA-IR）水平呈正相关。
本研究表明，低血清内脏脂肪素水平可能是II型糖尿病患者肾病的危险因素，而NO水平升高可能是DN中的一种防御机制。
